Physician profile
Amar B Dodda
NPI 1689940579
$18,794.68
in general payments reported to CMS, 2019-2025
35 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $397 · 2021: $329 · 2022: $9,514 · 2023: $4,067 · 2024: $3,427 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,100 · Food and Beverage: $3,438 · Education: $16.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,100.00 |
| Food and Beverage | $3,437.80 |
| Education | $16.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,500.55 | 2020-2025 | Exalt Model D, Apollo Esg System, Resolution 360 Clip |
| Abbvie INC. | $1,253.04 | 2021-2025 | Linzess, Viberzi, Mavyret |
| Lilly USA, LLC | $205.63 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $160.89 | 2021-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $157.81 | 2023 | Rebyota |
| Medtronic, INC. | $145.46 | 2021-2024 | Endoflip |
| Gilead Sciences, INC. | $126.70 | 2021-2023 | |
| Merit Medical Systems INC | $120.29 | 2024 | |
| Aimmune Therapeutics, INC. | $111.51 | 2024-2025 | Zenpep |
| Celgene Corporation | $105.56 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $100.97 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $85.91 | 2025 | Iqirvo |
| Axonics, INC. | $73.85 | 2023 | Axonics |
| Davol INC. | $62.50 | 2023 | Arista Ah Flexitip |
| Nestle Healthcare Nutrition INC. | $57.15 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $56.07 | 2024 | Voquezna |
| Covidien LP | $50.06 | 2020 | |
| Conmed Corporation | $45.45 | 2023 | Airseal |
| Mallinckrodt Hospital Products INC. | $35.72 | 2025 | Terlivaz |
| Celltrion USA INC. | $32.59 | 2024 | Zymfentra, Vegzelma |
| Genzyme Corporation | $31.76 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.26 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $29.83 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $25.89 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $24.41 | 2024 | |
| Ironwood Pharmaceuticals, INC | $23.61 | 2023 | Linzess |
| Daiichi Sankyo INC. | $21.74 | 2021 | |
| Redhill Biopharma INC. | $20.95 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.90 | 2023 | Oxlumo |
| Pharmacosmos Therapeutics INC. | $18.45 | 2025 | Monoferric |
| Janssen Biotech, INC. | $17.26 | 2022 | |
| Capsovision, INC. | $14.02 | 2024 | Capsocam Plus |
| Evoke Pharma, INC. | $13.70 | 2024 | |
| Vivus LLC | $13.19 | 2024 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Dodda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.